Here are five key points:
1. The deal will fund the development of medications that help restore a healthy bacteriological balance in the human digestive system.
2. The medications will include experimental treatments for Clostridium difficile infection and inflammatory bowel disease.
3. The deal gives Nestle’s Health Science division exclusive rights to sell Seres’ treatments.
4. This is the third investment Nestle has made in Seres.
5. Nestle invested $65 million in January 2015 and bought an 18 percent stake in the company when Seres went public in summer 2015.
More articles on GI/endoscopy:
6 GI physicians in the news – Jan. 8, 2016
HOPDs vs. ASCs: 5 things to know about colonoscopy quality variation in outpatient facilities
Dr. Sandra Jara joins Gastroenterology Group of Naples
